Skip to main content

Advertisement

SpringerLink
Log in

Paraoxonase 1 Polymorphisms Are Not Related with the Risk for Multiple Sclerosis

  • Original Paper
  • Published:
NeuroMolecular Medicine Aims and scope Submit manuscript

Abstract

It has been suggested a possible role of oxidative stress and lipid peroxidation in the inflammatory processes and in the pathogenesis of multiple sclerosis. Human serum paraoxonase 1 is a polymorphic enzyme encoded by the gene PON1, located in chromosome 7q21.3, that plays a major role in the metabolism of organophosporus compounds, and in the protection against oxidative stress. Paraoxonase-1 activity has been found decreased in the plasma of multiple sclerosis patients. An association between PON1 polymorphism and the risk of multiple sclerosis has been described in Italians. To investigate the possible association between the PON1 genotype and allelic variants of the polymorphisms L55M and Q192R and the risk for multiple sclerosis in the Spanish Caucasian population; we studied the frequency of the PON1 genotypes and allelic variants in 228 patients with multiple sclerosis and 220 healthy controls using a PCR-RLFP method. The frequencies of the PON1 genotypes and allelic variants did not differ significantly between patients and controls, and were unrelated with gender, age of onset, and course of the disease. The OR (95% confidence intervals) for the variant alleles PON1-55L and PON1-192R were 0.96 (0.73–1.26) and 1.01 (0.76–1.35), respectively. The results of the present study suggest that PON1 polymorphism is not related with the risk for multiple sclerosis in our population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Adkins, S., Gan, K. N., Mody, M., & La Du, B. N. (1993). Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: Glutamine or arginine at position 191, for the respective A or B allozymes. American Journal of Human Genetics, 52, 598–608.

    CAS  PubMed  Google Scholar 

  • Akhmedova, S., Anisimov, S., Yakimovsky, A., & Schwartz, E. (1999). Gln → Arg 191 polymorphism of paraoxonase and Parkinson’s disease. Human Heredity, 49, 178–180.

    Article  CAS  PubMed  Google Scholar 

  • Akhmedova, S. N., Yakimovsky, A. K., & Schwartz, E. I. (2001). Paraoxonase 1 Met–Leu 54 polymorphism is associated with Parkinson’s disease. Journal of the Neurological Sciences, 184, 179–182.

    Article  CAS  PubMed  Google Scholar 

  • Amorini, A. M., Petzold, A., Tavazzi, B., Eikelenboom, J., Keir, G., Belli, A., et al. (2009). Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. Clinical Biochemistry, 42, 1001–1006.

    Article  CAS  PubMed  Google Scholar 

  • Bizzozero, O. A., DeJesus, G., Callahan, K., & Pastuszyn, A. (2005). Elevated protein carbonylation in the brain white matter and gray matter of patients with multiple sclerosis. Journal of Neuroscience Research, 81, 687–695.

    Article  CAS  PubMed  Google Scholar 

  • Bulpitt, C. J. (1987). Confidence intervals. Lancet, 1, 494–497.

    Article  CAS  PubMed  Google Scholar 

  • Calabrese, V., Raffaele, R., Cosentino, E., & Rizza, V. (1994). Changes in cerebrospinal fluid levels of malondialdehyde and glutathione reductase activity in multiple sclerosis. International Journal of Clinical Pharmacology Research, 14, 119–123.

    CAS  PubMed  Google Scholar 

  • Can Demirdöğen, B., Türkanoğlu, A., Bek, S., Sanisoğlu, Y., Demirkaya, S., Vural, O., et al. (2008). Paraoxonase/arylesterase ratio, PON1 192Q/R polymorphism and PON1 status are associated with increased risk of ischemic stroke. Clinical Biochemistry, 41, 1–9.

    Article  PubMed  Google Scholar 

  • Carmine, A., Buervenich, S., Sydow, O., Anvret, M., & Olson, L. (2002). Further evidence for an association of the paraoxonase 1 (PON1) Met-54 allele with Parkinson’s disease. Movement Disorders, 17, 764–766.

    Article  PubMed  Google Scholar 

  • Clarimon, J., Eerola, J., Hellstrom, O., Tienari, P. J., & Singleton, A. (2004). Paraoxonase 1 (PON1) gene polymorphisms and Parkinson’s disease in a Finnish population. Neuroscience Letters, 367, 168–170.

    Article  CAS  PubMed  Google Scholar 

  • Cowan, J., Sinton, C. M., Varley, A. W., Wians, F. H., Haley, R. W., & Munford, R. S. (2001). Gene therapy to prevent organophosphate intoxication. Toxicology and Applied Pharmacology, 173, 1–6.

    Article  CAS  PubMed  Google Scholar 

  • Dantoine, T. F., Drouet, M., Debord, J., Merle, L., Cogne, M., & Charmes, J. P. (2002). Paraoxonase 1 192/55 gene polymorphisms in Alzheimer’s disease. Annals of the New York Academy of Sciences, 977, 239–244.

    Article  CAS  PubMed  Google Scholar 

  • de Bustos, F., Navarro, J. A., de Andrés, C., Molina, J. A., Jiménez-Jiménez, F. J., Ortí-Pareja, M., et al. (1999). Cerebrospinal fluid nitrate levels in patients with multiple sclerosis. European Neurology, 41, 44–47.

    Article  PubMed  Google Scholar 

  • Diekstra, F. P., Beleza-Meireles, A., Leigh, N. P., Shaw, C. E., & Al-Chalabi, A. (2009). Interaction between PON1 and population density in amyotrophic lateral sclerosis. Neuroreport, 20, 186–190.

    Article  CAS  PubMed  Google Scholar 

  • Duric, G., Svetel, M., Nikolaevic, S. I., Dragadevic, N., Gavrilovic, J., & Kostic, V. S. (2007). Polymorphisms in the genes of cytochrome oxidase P450 2D6 (CYP2D6), paraoxonase 1 (PON1) and apolipoprotein E (APOE) as risk factors for Parkinson’s disease. Vojnosanitetski Pregled, 64, 25–30.

    Google Scholar 

  • Dyment, D. A., Ebers, G. C., & Sadovnick, A. D. (2004). Genetics of multiple sclerosis. Lancet Neurology, 3, 104–110.

    Article  CAS  PubMed  Google Scholar 

  • Erlich, P. M., Lunetta, K. L., Cupples, L. A., Huyck, M., Green, R. C., Baldwin, C. T., et al. (2006). Polymorphisms in the PON gene cluster are associated with Alzheimer disease. Human Molecular Genetics, 15, 77–85.

    Article  CAS  PubMed  Google Scholar 

  • Ferretti, G., Bacchetti, T., Principi, F., Di Ludovico, F., Viti, B., Angeleri, V. A., et al. (2005). Increased levels of lipid hydroperoxydes in plasma of patients with multiple sclerosis: A relationship with paraoxonase activity. Multiple Sclerosis, 11, 677–682.

    Article  CAS  PubMed  Google Scholar 

  • Fong, C. S., Cheng, C. W., & Wu, R. M. (2005). Pesticides exposure and genetic polymorphism of paraoxonase in the susceptibility of Parkinson’s disease. Acta Neurologica (Taiwan), 14, 55–60.

    Google Scholar 

  • Giordano, M., D’Alfonso, S., & Momigliano-Richiardi, P. (2002). Genetics of multiple sclerosis: linkage and association studies. American Journal of Pharmacogenomics, 2, 37–58.

    Article  CAS  PubMed  Google Scholar 

  • Greco, A., Minghetti, L., Puopolo, M., Cannoni, S., Romano, S., Pozzilli, C., et al. (2004). Cerebrospinal fluid isoprostanes are not related to inflammatory activity in relapsing-remitting multiple sclerosis. Journal of the Neurological Sciences, 224, 23–27.

    Article  CAS  PubMed  Google Scholar 

  • Hadjigeorgiou, G. M., Malizos, K., Dardiotis, E., Aggelakis, K., Dardioti, M., Zibis, A., et al. (2007). Paraoxonase 1 gene polymorphisms in patients with osteonecrosis of the femoral head with and without cerebral white matter lesions. Journal of Orthopaedic Research, 25, 1087–1093.

    Article  CAS  PubMed  Google Scholar 

  • Helbecque, N., Cottel, D., Codron, V., Berr, C., & Amouyel, P. (2004). Paraoxonase 1 gene polymorphisms and dementia in humans. Neuroscience Letters, 358, 41–44.

    Article  CAS  PubMed  Google Scholar 

  • Huang, Q., Liu, Y. H., Yang, Q. D., Xiao, B., Ge, L., Zhang, N., et al. (2006). Human serum paraoxonase gene polymorphisms, Q192R and L55M, are not associated with the risk of cerebral infarction in Chinese Han population. Neurological Research, 28, 549–554.

    Article  CAS  PubMed  Google Scholar 

  • Humbert, R., Adler, D. A., Disteche, C. M., Hassett, C., Omiecinski, C. J., & Furlong, C. E. (1993). The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genetics, 3, 73–76.

    Article  CAS  PubMed  Google Scholar 

  • Jiménez-Jiménez, F. J., de Bustos, F., Molina, J. A., de Andrés, C., Gasalla, T., Ortí-Pareja, M., et al. (1998). Cerebrospinal fluid levels of alpha-tocopherol in patients with multiple sclerosis. Neuroscience Letters, 249, 65–67.

    Article  PubMed  Google Scholar 

  • Kalousová, M., Havrdová, E., Mrázová, K., Spacek, P., Braun, M., Uhrová, J., et al. (2005). Advanced glycoxidation end products in patients with multiple sclerosis. Prague Medical Report, 106, 167–174.

    PubMed  Google Scholar 

  • Kastenbauer, S., Kieseier, B. C., & Becker, B. F. (2005). No evidence of increased oxidative degradation of urate to allantoin in the CSF and serum of patients with multiple sclerosis. Journal of Neurology, 252, 611–612.

    Article  PubMed  Google Scholar 

  • Kelada, S. N., Costa-Mallén, P., Checkoway, H., Viernes, H. A., Farin, F. M., Smith-Weller, T., et al. (2003). Paraoxonase 1 promoter and coding region polymorphisms in Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry, 74, 545–548.

    Article  Google Scholar 

  • Kondo, I., & Yamamoto, M. (1998). Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson’s disease. Brain Research, 806, 271–273.

    Article  CAS  PubMed  Google Scholar 

  • Kucukali, C. I., Aydin, M., Ozkok, E., Orhan, N., Cakir, U., Kilic, G., et al. (2008). Paraoxonase-1 55/192 genotypes in schizophrenic patients and their relatives in Turkish population. Psychiatric Genetics, 18, 289–294.

    Article  PubMed  Google Scholar 

  • La Du, B. N. (1992). Human serum paraoxonase/arylesterase. In W. Kalow (Ed.), Pharmacogenetics of drugs metabolism (pp. 51–91). New York: Pergamon Press.

    Google Scholar 

  • Langemann, H., Kabiersch, A., & Newcombe, J. (1992). Measurement of low molecular-weight antioxidants, uric acid, tyrosine and tryptophan in plaques and white matter from patients with multiple sclerosis. European Neurology, 32, 248–252.

    Article  CAS  PubMed  Google Scholar 

  • Leduc, V., & Poirier, J. (2008). Polymorphisms at the paraoxonase 1 L55 M and Q192R loci affect the pathophysiology of Alzheimer’s disease: Emphasis on the cholinergic system and beta-amyloid levels. Neurodegeneration Diseases, 5, 225–227.

    Article  CAS  Google Scholar 

  • LeVine, S. M. (1992). The role of reactive oxygen species in the pathogenesis of multiple sclerosis. Medical Hypotheses, 39, 271–274.

    Article  CAS  PubMed  Google Scholar 

  • Li, H. L., Liu, D. P., & Liang, C. C. (2003). Paraoxonase gene polymorphisms, oxidative stress, and diseases. Journal of Molecular Medicine, 81, 766–779.

    Article  CAS  PubMed  Google Scholar 

  • Mackness, B., Durrington, P. N., & Mackness, M. I. (2002). The paraoxonase gene family and coronary heart disease. Current Opinion in Lipidology, 13, 357–362.

    Article  CAS  PubMed  Google Scholar 

  • Mackness, B., Mackness, M. I., Arrol, S., Turkie, W., Julier, K., Abuasha, B., et al. (1998). Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis, 139, 341–349.

    Article  CAS  PubMed  Google Scholar 

  • Mackness, M. I., Mackness, B., Durrington, P. N., Connelly, P. W., & Hegele, R. A. (1996). Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Current Opinion in Lipidology, 7, 69–76.

    Article  CAS  PubMed  Google Scholar 

  • Mattsson, N., Haghighi, S., Andersen, O., Yao, Y., Rosengren, L., Blennow, K., et al. (2007). Elevated cerebrospinal fluid F2-isoprostane levels indicating oxidative stress in healthy siblings of multiple sclerosis patients. Neuroscience Letters, 414, 233–236.

    Article  CAS  PubMed  Google Scholar 

  • McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H. P., Lublin, F. B., et al. (2001). Recommended diagnostic criteria for multiple sclerosis guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Annals of Neurology, 50, 121–127.

    Article  CAS  PubMed  Google Scholar 

  • Newcombe, J., Li, H., & Cuzner, M. L. (1994). Low density lipoprotein uptake by macrophages in multiple sclerosis plaques: Implications for pathogenesis. Neuropathology and Applied Neurobiology, 20, 152–162.

    Article  CAS  PubMed  Google Scholar 

  • Pértegas-Díaz, S., & Pita-Fernández, S. (2003). Cálculo del poder estadístico de un estudio. Cadernos de Atención Primaria, 10, 59–63.

    Google Scholar 

  • Pugliatti, M., Harbo, H. F., Holmøy, T., Kampman, M. T., Myhr, K. M., Riise, T., et al. (2008). Environmental risk factors in multiple sclerosis. Acta Neurologica Scandinavica Supplement, 188, 34–40.

    Article  CAS  Google Scholar 

  • Ramagopalan, S. V., Deluca, G. C., Degenhardt, A., & Ebers, G. C. (2008). The genetics of clinical outcome in multiple sclerosis. Journal of Neuroimmunology, 201–202, 183–199.

    Article  PubMed  Google Scholar 

  • Schmidt, R., Schmidt, H., Fazekas, F., Kapeller, P., Roob, G., Lechner, A., et al. (2000). MRI cerebral white matter lesions and paraoxonase PON1 polymorphisms: Three-year follow-up of the austrian stroke prevention study. Arteriosclerosis, Thrombosis, and Vascular Biology, 20, 1811–1816.

    CAS  PubMed  Google Scholar 

  • Shin, B. S., Oh, S. Y., Kim, Y. S., & Kim, K. W. (2008). The paraoxonase gene polymorphism in stroke patients and lipid profile. Acta Neurologica Scandinavica, 117, 237–243.

    Article  CAS  PubMed  Google Scholar 

  • Sidoti, A., Antognelli, C., Rinaldi, C., D’Angelo, R., Dattola, V., Girlanda, P., et al. (2007). Glyoxalase I A111E, paraoxonase 1 Q192R and L55M polymorphisms: susceptibility factors of multiple sclerosis? Multiple Sclerosis, 13, 446–453.

    CAS  PubMed  Google Scholar 

  • Taylor, M. C., Le Couteur, D. G., Mekkick, G. D., & Board, P. G. (2000). Paraoxonase polymorphisms, pesticide exposure and Parkinson’s disease in a Caucasian population. Journal of Neural Transmission, 107, 979–983.

    Article  CAS  PubMed  Google Scholar 

  • Toshniwal, P. K., & Zarling, E. J. (1992). Evidence for increased lipid peroxidation in multiple sclerosis. Neurochemical Research, 17, 205–207.

    Article  CAS  PubMed  Google Scholar 

  • Ueno, T., Shimazaki, E., Matsumoto, T., Watanabe, H., Tsunemi, A., Takahashi, Y., et al. (2003). Paraoxonase 1 polymorphism Leu-Met55 is associated with cerebral infarction in Japanese population. Medical Science Monitor, 9, CR208–212.

  • van Horssen, J., Schreibelt, G., Bö, L., Montagne, L., Drukarch, B., van Muiswinkel, F. L., et al. (2006). NAD(P)H:quinone oxidoreductase 1 expression in multiple sclerosis lesions. Free Radical Biology and Medicine, 41, 311–317.

    Article  PubMed  Google Scholar 

  • van Horssen, J., Schreibelt, G., Drexhage, J., Hazes, T., Dijkstra, C. D., van der Valk, P., et al. (2008). Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radical Biology and Medicine, 45, 1729–1737.

    Article  PubMed  Google Scholar 

  • Wang, J., & Liu, Z. (2000). No association between paraoxonase 1 (PON1) gene polymorphisms and susceptibility to Parkinson’s disease in a Chinese population. Movement Disorders, 15, 1265–1267.

    Article  CAS  PubMed  Google Scholar 

  • Wills, A. M., Cronin, S., Slowik, A., Kasperaviciute, D., Van Es, M. A., Morahan, J. M., et al. (2009). A large-scale international meta-analysis of paraoxonase gene polymorphisms in sporadic ALS. Neurology, 73, 16–24.

    Article  CAS  PubMed  Google Scholar 

  • Zintzaras, E., & Hadjigeorgiou, G. M. (2004). Association of paraoxonase 1 gene polymorphisms with risk of Parkinson’s disease: A meta-analysis. Journal of Human Genetics, 49, 474–481.

    Article  PubMed  Google Scholar 

  • Zuliani, G., Ble’, A., Zanca, R., Munari, M. R., Zurlo, A., Vavalle, C., et al. (2001). Genetic polymorphisms in older subjects with vascular or Alzheimer’s dementia. Acta Neurologica Scandinavica, 103, 304–308.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported in part by Grants FIS 05/1056, 06/1252, and RETICS RD07/0064/0016 from Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Spain and FUNDESALUD, Mérida, Spain.

Author information

Authors and Affiliations

  1. Department of Pharmacology & Psychiatry, Medical School, University of Extremadura, Badajoz, Spain

    Carmen Martínez & José A. G. Agúndez

  2. Department of Biochemistry and Molecular Biology, School of Biological Sciences, University of Extremadura, Badajoz, Spain

    Elena García-Martín

  3. Department of Neurology, Hospital Universitario Doce de Octubre, Madrid, Spain

    Julián Benito-León, Patricia Calleja & María Díaz-Sánchez

  4. Centro de Biología Molecular Severo Ochoa (CSIC-UAM), Facultad de Ciencias, Universidad Autónoma, Cantoblanco, 28049, Madrid, Spain

    Diana Pisa

  5. Department of Medicine-Neurology, Hospital “Príncipe de Asturias”, Universidad de Alcalá, Alcalá de Henares, Madrid, Spain

    Hortensia Alonso-Navarro, Lucía Ayuso-Peralta, Dolores Torrecilla & Félix Javier Jiménez-Jiménez

  6. Section of Neurology, Hospital La Mancha-Centro, Alcázar de San Juan, Ciudad Real, Spain

    Hortensia Alonso-Navarro

  7. Section of Neurology, Hospital del Sureste, Arganda del Rey, Madrid, Spain

    Félix Javier Jiménez-Jiménez

  8. C/Marroquina 14, 3° B, 28030, Madrid, Spain

    Félix Javier Jiménez-Jiménez

Authors
  1. Carmen Martínez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elena García-Martín
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Julián Benito-León
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Patricia Calleja
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. María Díaz-Sánchez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Diana Pisa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hortensia Alonso-Navarro
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lucía Ayuso-Peralta
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Dolores Torrecilla
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. José A. G. Agúndez
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Félix Javier Jiménez-Jiménez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Félix Javier Jiménez-Jiménez.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Martínez, C., García-Martín, E., Benito-León, J. et al. Paraoxonase 1 Polymorphisms Are Not Related with the Risk for Multiple Sclerosis. Neuromol Med 12, 217–223 (2010). https://doi.org/10.1007/s12017-009-8095-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12017-009-8095-9

Keywords

Search

Navigation